Personalizing
Cancer Treatment for Everyone

Clinical trials to begin in human patients with brain cancer

The University's veterinary oncologist Timothy Fan and chemistry professor Paul Hergenrother have worked for over a decade on a new drug to combat brain cancer.

December 5, 2017

A drug has been cleared for use in a clinical trial by University faculty that will help treat brain cancer.

The drug, PAC-1, causes cancer cells to self-destruct and will be given to patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, a fast-growing, late-stage brain cancer.

University veterinary oncologist Dr. Timothy Fan and chemistry professor Paul Hergenrother have been collaborating with their colleagues for 10 years to prepare the drug for clinical trials. The trial will be approved to patients with late-stage cancers whose condition worsened after first-line therapy, which is the initially accepted treatment regimen given for cancer.

Read More

Stay in Touch with Us
To speak with a dedicated cancer care specialist, contact us by one of the options listed below:
PLEASE FILL OUT FORM BELOW

X
Talk to Cancer Care Experts:
+1 (844) 627-7246
Top